Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Victoria Harding is active.

Publication


Featured researches published by Victoria Harding.


Gastroenterology | 2014

MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression

Adam E. Frampton; Leandro Castellano; Teresa Colombo; Elisa Giovannetti; Jonathan Krell; Jimmy Jacob; Loredana Pellegrino; Laura Roca-Alonso; Niccola Funel; Tamara Mh Gall; Alexander de Giorgio; Filipa G. Pinho; Valerio Fulci; David Britton; Raida Ahmad; Nagy Habib; R. Charles Coombes; Victoria Harding; Thomas Knösel; Justin Stebbing; Long R. Jiao

BACKGROUND & AIMS There has not been a broad analysis of the combined effects of altered activities of microRNAs (miRNAs) in pancreatic ductal adenocarcinoma (PDAC) cells, and it is unclear how these might affect tumor progression or patient outcomes. METHODS We combined data from miRNA and messenger RNA (mRNA) expression profiles and bioinformatic analyses to identify an miRNA-mRNA regulatory network in PDAC cell lines (PANC-1 and MIA PaCa-2) and in PDAC samples from patients. We used this information to identify miRNAs that contribute most to tumorigenesis. RESULTS We identified 3 miRNAs (MIR21, MIR23A, and MIR27A) that acted as cooperative repressors of a network of tumor suppressor genes that included PDCD4, BTG2, and NEDD4L. Inhibition of MIR21, MIR23A, and MIR27A had synergistic effects in reducing proliferation of PDAC cells in culture and growth of xenograft tumors in mice. The level of inhibition was greater than that of inhibition of MIR21 alone. In 91 PDAC samples from patients, high levels of a combination of MIR21, MIR23A, and MIR27A were associated with shorter survival times after surgical resection. CONCLUSIONS In an integrated data analysis, we identified functional miRNA-mRNA interactions that contribute to growth of PDACs. These findings indicate that miRNAs act together to promote tumor progression; therapeutic strategies might require inhibition of several miRNAs.


Cancer | 2014

Patient-derived xenografts for individualized care in advanced sarcoma

Justin Stebbing; Keren Paz; Gary K. Schwartz; Leonard H. Wexler; Robert G. Maki; Raphael E. Pollock; Ronnie Morris; Richard Cohen; Arjun Shankar; Glen Blackman; Victoria Harding; David Vasquez; Jonathan Krell; Daniel Ciznadija; Amanda M. Katz; David Sidransky

Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard‐of‐care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient‐derived xenografts using a proprietary method (“TumorGrafts”).


Molecular and Cellular Biology | 2013

Emerging Roles of Competing Endogenous RNAs in Cancer: Insights from the Regulation of PTEN

Alexander de Giorgio; Jonathan Krell; Victoria Harding; Justin Stebbing; Leandro Castellano

ABSTRACT The capacity of noncoding RNA to regulate gene expression in health and disease is epitomized by the microRNAs, small ∼22-nucleotide RNAs that target mRNAs to repress their translation into protein. Recently a previously unrecognized gene regulatory layer has emerged, characterized by the ability of a wide range of RNA transcripts to vie for microRNA binding and alleviate the repressive effect of microRNAs on their mRNA targets. Termed competing endogenous RNAs (ceRNAs), these participate in a microRNA-dependent cross talk, producing robust networks that when perturbed may lead to cancer. To date, the tumor suppressor PTEN has been most extensively validated as competing with a variety of ceRNAs in different cancers: reducing these ceRNAs appears to reduce PTEN levels, tipping cells toward cancer progression. In this review we look at ceRNA networks in cancer, their characteristics, and constituent parts, focusing on the insights that can be gained from the studies conducted on PTEN. We also explore the conditions that facilitate ceRNA cross talk, proposing that the disruption of these conditions may represent a general phenomenon in carcinogenesis.


Cancer Research | 2013

Downregulation of microRNA-515-5p by the Estrogen Receptor Modulates Sphingosine Kinase 1 and Breast Cancer Cell Proliferation

Filipa G. Pinho; Adam E. Frampton; Joao Nunes; Jonathan Krell; Heba Alshaker; Jimmy Jacob; Loredana Pellegrino; Laura Roca-Alonso; Alexander de Giorgio; Victoria Harding; Jonathan Waxman; Justin Stebbing; Dmitry Pchejetski; Leandro Castellano

Sphingosine kinase 1 (SK1) plays an important role in estrogen-dependent breast tumorigenesis, but its regulation is poorly understood. A subset of microRNAs (miRNA, miR) is regulated by estrogen and contributes to cellular proliferation and cancer progression. Here, we describe that miR-515-5p is transcriptionally repressed by estrogen receptor α (ERα) and functions as a tumor suppressor in breast cancer. Its downregulation enhances cell proliferation and estrogen-dependent SK1 activity, mediated by a reduction of miR-515-5p posttranscriptional repression. Enforced expression of miR-515-5p in breast cancer cells causes a reduction in SK1 activity, reduced cell proliferation, and the induction of caspase-dependent apoptosis. Conversely, opposing effects occur with miR-515-5p inhibition and by SK1 silencing. Notably, we show that estradiol (E2) treatment downregulates miR-515-5p levels, whereas the antiestrogen tamoxifen causes a decrease in SK1, which is rescued by silencing miR-515-5p. Analysis of chromatin immunoprecipitation sequencing (ChIP-Seq) data reveals that miR-515-5p suppression is mediated by a direct interaction of ERα within its promoter. RNA-sequencing (RNA-Seq) analysis of breast cancer cells after overexpressing miR-515-5p indicates that it partly modulates cell proliferation by regulating the Wnt pathway. The clinical implications of this novel regulatory system are shown as miR-515-5p is significantly downregulated in ER-positive (n = 146) compared with ER-negative (n = 98) breast cancers. Overall, we identify a new link between ERα, miR-515-5p, proliferation, and apoptosis in breast cancer tumorigenesis.


PLOS ONE | 2014

Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer

Jonathan Krell; Adam E. Frampton; Reza Mirnezami; Victoria Harding; Alex de Giorgio; Laura Roca Alonso; Patrizia Cohen; Silvia Ottaviani; Teresa Colombo; Jimmy Jacob; Loredana Pellegrino; Gordon N. Buchanan; Justin Stebbing; Leandro Castellano

Background The growth arrest-specific transcript 5 gene (GAS5) encodes a long noncoding RNA (lncRNA) and hosts a number of small nucleolar RNAs (snoRNAs) that have recently been implicated in multiple cellular processes and cancer. Here, we investigate the relationship between DNA damage, p53, and the GAS5 snoRNAs to gain further insight into the potential role of this locus in cell survival and oncogenesis both in vivo and in vitro. Methods We used quantitative techniques to analyse the effect of DNA damage on GAS5 snoRNA expression and to assess the relationship between p53 and the GAS5 snoRNAs in cancer cell lines and in normal, pre-malignant, and malignant human colorectal tissue and used biological techniques to suggest potential roles for these snoRNAs in the DNA damage response. Results GAS5-derived snoRNA expression was induced by DNA damage in a p53-dependent manner in colorectal cancer cell lines and their levels were not affected by DICER. Furthermore, p53 levels strongly correlated with GAS5-derived snoRNA expression in colorectal tissue. Conclusions In aggregate, these data suggest that the GAS5-derived snoRNAs are under control of p53 and that they have an important role in mediating the p53 response to DNA damage, which may not relate to their function in the ribosome. We suggest that these snoRNAs are not processed by DICER to form smaller snoRNA-derived RNAs with microRNA (miRNA)-like functions, but their precise role requires further evaluation. Furthermore, since GAS5 host snoRNAs are often used as endogenous controls in qPCR quantifications we show that their use as housekeeping genes in DNA damage experiments can lead to inaccurate results.


Epigenomics | 2013

The p53 miRNA interactome and its potential role in the cancer clinic

Jonathan Krell; Adam E. Frampton; Teresa Colombo; Tamara Mh Gall; Alex de Giorgio; Victoria Harding; Justin Stebbing; Leandro Castellano

p53 is one of the most frequently mutated tumor suppressors. It regulates protein-coding genes and noncoding RNAs involved in many cellular processes, functioning predominantly at the transcriptional level but also through nontranscriptional processes. miRNAs have recently been identified as key mediators of the p53 stress-response pathway. p53 regulates miRNA transcription and processing, and miRNAs regulate p53 activity and expression and, accordingly, various feedback/feed-forward loops have been identified. Many chemotherapeutic agents induce cancer cell death or senescence via DNA damage and the subsequent activation of p53. Resistance to chemotherapy can occur due to the mutation of components in p53 signaling networks. A better understanding of the role of the various components within these pathways and their interactions with each other may allow the modification and improvement of current treatments, and the design of novel therapies. Improving our knowledge of the role of miRNAs in such p53 signaling networks may be crucial to achieving this.


Genome Research | 2016

TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network.

Jonathan Krell; Justin Stebbing; Claudia Carissimi; Aleksandra Dabrowska; Alexander de Giorgio; Adam E. Frampton; Victoria Harding; Valerio Fulci; Giuseppe Macino; Teresa Colombo; Leandro Castellano

DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2s association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.


The Lancet | 2015

The role of TP53 in miRNA loading onto AGO2 and in remodelling the miRNA-mRNA interaction network.

Jonathan Krell; Justin Stebbing; Adam E. Frampton; Claudia Carissimi; Victoria Harding; Alexander de Giorgio; Valerio Fulci; Giuseppe Macino; Teresa Colombo; Leandro Castellano

BACKGROUND DNA damage transactivates tumour protein p53 (TP53)-regulated surveillance, crucial in suppressing tumorigenesis. TP53 mediates this process directly by transcriptionally modulating gene and microRNA (miRNA) expression and indirectly by regulating miRNA biogenesis. However, the role of TP53 in regulating miRNA-AGO2 loading and global changes in AGO2 binding to its gene targets in response to DNA damage are unknown. These processes might be novel mechanisms by which TP53 regulates miRNAs in response to DNA damage. METHODS To show the network of miRNA-mRNA interactions that occur in response to DNA damage, we stimulated TP53 wild-type and null cell-lines with doxorubicin and performed RNA sequencing from total RNA (RNA-Seq) and AGO2-immunoprecipitated RNA (AGO2-RIP-Seq). We used a combined AGO2 RIP-seq and AGO2 PAR-CLIP-seq (photoactivatable-ribonucleoside-enhanced cross-linking and immunoprecipitation) approach to determine the exact sites of interaction between the AGO2-bound miRNAs and their mRNA targets. FINDINGS TP53 directly associated with AGO2, and induced and reduced loading of a subset of miRNAs, including the lethal 7 (let-7) miRNA family members, onto AGO2 in response to DNA damage. Although mutated TP53 maintained its capacity to interact with AGO2, it mediated unloading instead of loading of let-7 family miRNAs, thereby reducing their activity. We determined the miRNA-mRNA interaction networks involved in the response to DNA damage both in the presence and absence of TP53. Furthermore, we showed that miRNAs whose cellular abundance or differential loading onto AGO2 was regulated by TP53 were involved in an intricate network of regulatory feedback and feedforward circuits that fine-tuned gene expression levels in response to DNA damage to permit the repair of DNA damage or initiation of programmed cell death. INTERPRETATION Control of AGO2 loading by TP53 is a new mechanism of miRNA regulation in carcinogenesis. FUNDING UK Medical Research Council, Action Against Cancer.


Journal of Molecular Endocrinology | 2014

Noncoding RNAs and the control of hormonal signaling via nuclear receptor regulation

Silvia Ottaviani; Alexander de Giorgio; Victoria Harding; Justin Stebbing; Leandro Castellano

Despite its identification over 100 years ago, new discoveries continue to add to the complexity of the regulation of the endocrine system. Today the nuclear receptors (NRs) that play such a pivotal role in the extensive communication networks of hormones and gene expression remain an area of intense research. By orchestrating core processes, from metabolism to organismal development, the gene expression programs they control are dependent on their cellular context, their own levels, and those of numerous co-regulatory proteins. A previously unknown component of these networks, noncoding RNAs (ncRNAs) are now recognized as potent regulators of NR signaling, influencing receptor and co-factor levels and functions while being reciprocally regulated by the NRs themselves. This review explores the regulation enacted by microRNAs and long ncRNAs on NR function, using representative examples to show the varied roles of ncRNAs, in turn producing significant effects on the NR functional network in health and disease.


Journal of Clinical Oncology | 2012

Cerebral Sinus Thrombosis and Leptomeningeal Carcinomatosis in a Patient With Ovarian Cancer

Ho Kwong Li; Victoria Harding; Ruth Williamson; Sarah Blagden; Hani Gabra; Roshan Agarwal

Case Report A 60-year-old Asian woman with a history of ovarian cancer presented with headaches and vomiting. She had a past medical history of pulmonary tuberculosis (TB) at age 20 years and was diagnosed with grade 2, stage IIIC serous ovarian cancer. At the time of her cancer diagnosis, her Ca125 was 1,326 IU/mL, and she underwent primary debulking surgery followed by six cycles of adjuvant carboplatin plus paclitaxel chemotherapy. Two years later, her disease relapsed with a Ca125 of 623 IU/mL, and she received six cycles of carboplatin plus liposomal doxorubicin with a complete response. Six months after completing chemotherapy, she presented with a 3-week history of headaches and vomiting and a Ca125 of 93 IU/mL. Examination demonstrated no focal neurologic deficits, and brain computed tomography (CT) and magnetic resonance imaging (MRI) showed no evidence of CNS metastases or systemic relapse on restaging. The clinical differential diagnoses were as follows: carcinomatous meningitis, tuberculous meningitis in view of her previous medical history, and/or cerebral sinus thrombosis (CST). A high opening pressure of 44 cm of H2O with lymphocytosis and increased protein (1.24 g/L) in the CSF was observed on lumbar puncture. Cytology for malignant cells was negative. Microbiology did not reveal acid-fast bacilli, and TB polymerase chain reaction was negative. In view of the markedly raised CSF pressure, a magnetic resonance venogram (MRV) and CT venogram were

Collaboration


Dive into the Victoria Harding's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Teresa Colombo

National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Valerio Fulci

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge